文献速递前列腺癌

磁共振超声融合活检中重叠对系统活检与靶向活检作用的影响

The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

回顾性分析240例接受Artemis平台融合活检的男性,将重叠的系统穿刺针重新归类为靶向穿刺针后,仅14例(5.8%)系统活检Gleason分级更高,其中7例(2.9%)从良性升级、3例(1.3%)从临床不显著癌升级。既往阴性活检与系统活检无临床显著前列腺癌(CSPC)相关(OR 0.46,95%CI 0.21-0.99;p=0.046),年龄与升级相关(OR 1.11,95%CI 1.02-1.21;p=0.015)。作者认为在既往阴性活检男性中可考虑仅靶向融合活检策略。

要点

  • 重叠系统穿刺针重新归类后,14例(5.8%)系统活检Gleason分级更高。
  • 既往阴性活检与系统活检无CSPC相关(OR 0.46,95%CI 0.21-0.99;p=0.046)。
  • 年龄与系统活检升级相关(OR 1.11,95%CI 1.02-1.21;p=0.015)。

核心结论

  • 在融合活检男性中,可能影响临床决策的系统活检CSPC检出不常见。
  • 作者认为,既往阴性活检男性因系统活检产出低,可考虑仅靶向融合活检策略。

研究设计与样本

  • 回顾性研究纳入240例接受Artemis平台融合活检的男性。
  • 软件捕获活检分布图,回顾分布图确定与ROI重叠的系统穿刺针,重叠系统穿刺针的组织病理学重新归类为ROI穿刺针。

主要发现

  • 与ROI重叠的系统穿刺针中位数为2(四分位距1-2)。
  • 校正重叠后,14例(5.8%)系统活检Gleason分级更高,其中7例(2.9%)从良性升级、3例(1.3%)从临床不显著癌升级。
  • 校正分析中,既往阴性活检与系统活检无CSPC相关(OR 0.46,95%CI 0.21-0.99;p=0.046)。
  • 校正分析中,年龄与升级相关(OR 1.11,95%CI 1.02-1.21;p=0.015)。

关键数值与推荐

  • 系统活检CSPC检出为结局指标。
  • 多变量逻辑回归用于分析年龄、前列腺特异性抗原、前列腺体积、既往活检状态和PI-RADS分类与CSPC检出及系统活检Gleason分级升级的关联。

临床怎么用

  • 作者认为,在既往阴性活检男性中,因系统活检产出低,可考虑仅靶向融合活检策略。

局限性

  • 局限性包括回顾性数据。
  • 局限性包括使用单一活检平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The value of a systematic biopsy in men with magnetic resonance imaging (MRI)-visible regions of interest (ROIs) undergoing fusion biopsy (FBx) is unclear. OBJECTIVE: To determine the utility of concurrent systematic biopsy with ROI biopsy in detecting clinically significant prostate cancer (CSPC). DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of 240 men who underwent FBx with the Artemis platform. Software captured biopsy distribution maps. Biopsy distribution maps were reviewed to determine which systematic cores overlapped with the ROI. Histopathology for overlapping systematic cores were reclassified as ROI cores. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Detection of CSPC on true systematic biopsy was the outcome measured. Multivariable logistic regression was used to determine if age, prostate-specific antigen, prostate volume, prior biopsy status, and Prostate Imaging-Reporting and Data System categorization were associated with CSPC detection and Gleason grade upgrading on systematic biopsy. RESULTS AND LIMITATIONS: The median number of systematic cores overlapping with ROIs was 2 (interquartile range 1-2). After accounting for overlap, 14 men (5.8%) had a higher Gleason grade on systematic biopsy. Of these, seven (2.9%) were upgraded from benign and three (1.3%) from clinically insignificant cancer on systematic biopsy. In adjusted analysis, prior negative biopsy (odds ratio [OR] 0.46, 95% confidence interval [CI] 0.21-0.99; p=0.046) was associated with absence of CSPC on systematic biopsy, while age (OR 1.11, 95% CI 1.02-1.21; p=0.015) was associated with upgrading. Limitations include the retrospective data and the use of a single biopsy platform. CONCLUSIONS: Detection of CSPC on systematic biopsy that might influence clinical decision-making is uncommon in men undergoing FBx. In men with a prior negative biopsy, a target-only FBx strategy could be considered because of the low yield on systematic biopsy. PATIENT SUMMARY: We found that random prostate sampling adds little diagnostic value in men who are undergoing a targeted biopsy of suspicious lesions found on imaging, especially for men who have had a prior negative biopsy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Patel N, Cricco-Lizza E, Kasabwala K, et al. The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy. Eur Urol Oncol. 2018. PMID: 31100246. doi:10.1016/j.euo.2018.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。